Blogs
Bioanalysis sits at the intersection of science, regulation, and application. As therapeutic modalities grow more complex and development timelines compress, the role of bioanalysis continues to expand beyond data generation into strategic enablement. To better understand what lies ahead, we asked a diverse group of leaders across KCAS…
Blogs
Global drug development now operates across borders by default. Pharmaceutical and biotech R&D routinely spans multiple countries, driven by competitive timelines, access to patients, and the need for specialized expertise. Governments have responded by actively courting development programs through incentives, talent investment, and streamlined infrastructure. Australia remains a strong…
Podcasts
John and Dom introduce guest Brad Nawa (Alamar Biosciences) to explain the NULISA™ platform, an ultra-sensitive platform for protein quantitation that aims to outperform earlier “ultra-sensitive” tools that often didn’t translate well in practice. Brad notes the platform is still antibody/content-driven, but differentiates itself by reducing background through a…
Podcasts
In the latest episode of the Weekly Bioanalysis podcast, Dom and John break down their biggest takeaways from the recent AAPS and EBF meetings, sharing what stood out across the scientific sessions, exhibition floors, and industry conversations. They discuss the major themes shaping bioanalysis right now, from emerging technologies…
Podcasts
In this episode, hosts Dom and John welcome Jason Hannah, Director of Marketing at KCAS Bio, to discuss the company’s strategy for navigating the 2025 global conference season. With major events like AAPS PharmSci 360 in the U.S. and the European Bioanalysis Forum (EBF) in Barcelona on the horizon,…
Podcasts
During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven…
Podcasts
In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the “gray areas” of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and…
Podcasts
In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an…
Podcasts
In Episode 89 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio’s strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company’s…
Podcasts
In this milestone 20th episode of “The Conversational Flow” podcast, hosts Adam and Brian dive into impactful developments across oncology, regulatory science, and bioanalytical innovation. The episode begins with a highlight of a recent major Keytruda study showing the first significant improvement in head and neck squamous cell carcinoma…
Podcasts
In the 19th episode of “The Conversational Flow”, our hosts, Brian and Adam, dive into the utility and innovation behind backbone panels in spectral flow cytometry, spotlighting a recent paper from BMS that presents a robust, flexible assay designed for immune monitoring using the Aurora platform. They discuss how…
Podcasts
In this engaging episode of the podcast, hosts Brian Wile and Adam Cotty welcome special guests Michael Naso, Hillary Quinn, and Barry Morse from The Therapeutic Innovations Group—a powerhouse team of scientists and biotech veterans with decades of experience across biologics, small molecules, and cell therapy. The conversation dives…